Table 3.
Demographics, Clinical Features, and Outcomes Between Transplant and Non-transplant Recipients Hospitalized for COVID-19 after Adjustment for Baseline eGFR and Comorbidities
| Cases n = 20 |
Controls n = 20 |
P Value | |
|---|---|---|---|
| Transplant age (mo) | 63 ± 47.85 | - | - |
| TbStDx (d)* | 4.3 ± 3.01 | 5.47 ± 3.93 | .17 |
| ICU admission n (%) | 6 (30) | 2 (10) | .11 |
| Creatinine at dx (mg/dL) | 2.19 (9.83-0.84 | 1.41 (8.9-0.5) | .38 |
| eGFR at dx (mL/min) | 44.5 ± 21.63 | 44.59 ± 23.69 | .88 |
| IL-6 (pg/mL) | 91.05 (1682-2.6) | 33.4 (210-4.4) | .38 |
| Reactive C protein (mg/l) | 96.7 ± 80.12 | 163.06 ± 109.56 | .03† |
| Leukocyte count (cells*10³/mm³) | 8.35 ± 5.54 | 10.86 ± 6.14 | .18 |
| Hemoglobin (gr/dL) | 12.96 ± 2.27 | 12.64 ± 2.12 | .89 |
| Platelet count (cells*10³/mm³) | 212.3 ± 153.02 | 229.5 ± 95.93 | .67 |
| Lactate deshidrogenase (U/L) | 620.65 ± 254.45 | 605.28 ± 412.41 | .12 |
| D-dimer (ng/mL) | 237 (2726-100) | 352 (46768-130) | .06 |
| MULBSTA score | 9.9 ± 3.66 | 10.23 ± 4.22 | .38 |
| Horowitz index | 287.84 ± 100.33 | 269.38 ± 106.56 | .62 |
| AKI at admission n (%) | 7 (35) | 10 (50) | .33 |
| Shock n (%) | 3 (15) | 2 (10) | .63 |
| Ventilatory support/O2 therapy n (%) | 10 | 7 | |
| High flow nasal cannula O2 | 4 (40) | 6 (85.71) | .18 |
| Non-invasive mechanical ventilation | 3 (30) | 1 (14.28) | |
| Invasive mechanical ventilation | 3 (30) | 0 (0) | |
| AKI during follow-up n (%) | 5 (25) | 6 (30) | .5 |
| CVVHD/HD n (%) | 1 (5) | 2 (10) | .54 |
| Concomitant infection n (%) | 6 (30) | 6 (30) | .63 |
| COVID-19 pharmacologic therapy n(%) | |||
| Tocilizumab | 10 (50) | 3 (15) | .02† |
| Dexamethasone | 17 (85) | 13 (65) | .14 |
| Initial dose (md/d) | 6 (15-0) | 6 (7.5-0) | .61 |
| Remdesivir | 8 (40) | 3 (15) | .07 |
| Hydroxychloroquine | 3 (15) | 1 (5) | .29 |
| Nosocomial infection n (%) | 4 (20) | 3 (15) | .67 |
| Opportunistic infection n (%) | 5 (25) | 1 (5) | .04† |
| Final creatinine (mg/dL) | 1.4 (4.8-0.7) | 1.2 (8-0.7) | .37 |
| Final eGFR (mL/min) | 53.35 ± 23.83 | 52.47 ± 29.8 | .3 |
| Hospitalization time (d) | 13.4 ± 7.01 | 11.65 ± 11.43 | .05 |
| Exitus n (%) | 6 (30) | 7 (35) | .73 |
| Sequels n (%) | 1 (7.1) | 0 (0) | .32 |
AKI, acute kidney injury; CVVHD, continuous veno-venous hemodialysis; eGFR, estimated glomerular filtration rate; HD, hemodialysis; ICU, intensive care unit; IL, interleukin; TbStDx, time between symptom onset to diagnosis.
⁎
TbStDx.
†
P < .05.